Bristol-Myers Squibb Company (BMY) Financials
Bristol-Myers Squibb Company (BMY) Historical Financial Statements and Key Metrics for 1987 - 2023
Full Bristol-Myers Squibb Company financials for 1987 - 2023 are available in the
US Historical Financials dataset
All financial data is sourced direct from SEC 10-Q and 10-K filings, restatements are included.
Bristol-Myers Squibb Company Income Statements
(in $ 000,000's)
| Quarter End | Revenue | Gross Profit | Operating Income | Net Income | EBITDA | EPS |
| 2023-Dec-31 | 11,477 | 8,732 (76.1 %) | 1,684 (14.7 %) | 1,762 (15.4 %) | 4,148 | 0.87 |
| 2023-Sep-30 | 10,966 | 8,460 (77.1 %) | 4,215 (38.4 %) | 1,928 (17.6 %) | 4,215 | 0.93 |
| 2023-Jun-30 | 11,226 | 8,350 (74.4 %) | 4,158 (37.0 %) | 2,073 (18.5 %) | 4,626 | 0.99 |
| 2023-Mar-31 | 11,337 | 8,771 (77.4 %) | 2,840 (25.1 %) | 2,262 (20.0 %) | 5,096 | 1.07 |
| 2022-Dec-31 | 11,406 | 8,813 (77.3 %) | 2,150 (18.8 %) | 2,022 (17.7 %) | 4,493 | 0.95 |
| 2022-Sep-30 | 11,218 | 8,865 (79.0 %) | 2,209 (19.7 %) | 1,606 (14.3 %) | 4,795 | 0.75 |
| 2022-Jun-30 | 11,887 | 9,167 (77.1 %) | 1,958 (16.5 %) | 1,421 (12.0 %) | 4,533 | 0.64 |
Full historical income statements for 1987 - 2023 is included in the
US Historical Financials dataset.
Bristol-Myers Squibb Company Balance Sheets
(in $ 000,000's)
| Quarter End | Total Assets | Total Liabilities | Total Debt | Total Equity | Cash & Equivalents |
| 2023-Dec-31 | 95,159 | 65,674 | 41,464 | 29,430 | 12,280 |
| 2023-Sep-30 | 91,263 | 62,201 | 39,267 | 28,998 | 7,685 |
| 2023-Jun-30 | 93,489 | 61,459 | 39,186 | 31,973 | 8,372 |
| 2023-Mar-31 | 94,281 | 62,395 | 39,371 | 31,824 | 8,995 |
| 2022-Dec-31 | 96,820 | 65,702 | 39,320 | 31,061 | 9,253 |
| 2022-Sep-30 | 98,196 | 65,462 | 39,098 | 32,671 | 9,027 |
| 2022-Jun-30 | 100,357 | 67,696 | 42,060 | 32,600 | 13,228 |
Full historical balance sheet data for 1987 - 2023 is included in the
US Historical Financials dataset.
Bristol-Myers Squibb Company Cash Flow Statements
(in $ 000,000's)
| Quarter End | Operating Cash Flow | Investing | Financing | Free Cash Flow |
| 2023-Dec-31 | 4,252 | -1,346 | 967 | 3,922 |
| 2023-Sep-30 | 4,751 | -410 | -5,160 | 4,409 |
| 2023-Jun-30 | 1,887 | -329 | -2,173 | 1,628 |
| 2023-Mar-31 | 2,970 | -210 | -3,050 | 2,692 |
| 2022-Dec-31 | 3,306 | 1,213 | -3,246 | 2,960 |
| 2022-Sep-30 | 3,687 | -2,081 | -4,543 | 3,440 |
| 2022-Jun-30 | 2,261 | -289 | -3,520 | 1,989 |
Full historical cash flow data for 1987 - 2023 is included in the
US Historical Financials dataset.
Bristol-Myers Squibb Company Key Valuation and Operating Metrics
| Quarter End | Market Capitalization ($ 000,000's) |
Enterprise Value ($ 000,000's) |
Price/Earnings ($ 000,000's) |
Price/Sales ($ 000,000's) |
Price/Book ($ 000,000's) |
| 2023-Dec-31 | 104,005 | 134,005 | 9.06 | 14.76 | 3.53 |
| 2023-Sep-30 | 119,388 | 151,141 | 10.89 | 15.48 | 4.12 |
| 2023-Jun-30 | 133,847 | 164,661 | 11.92 | 16.14 | 4.19 |
| 2023-Mar-31 | 145,482 | 175,858 | 12.83 | 16.08 | 4.57 |
| 2022-Dec-31 | 151,671 | 181,868 | 13.30 | 18.75 | 4.88 |
| 2022-Sep-30 | 151,635 | 182,999 | 13.52 | 23.60 | 4.64 |
| 2022-Jun-30 | 169,554 | 200,864 | 14.26 | 29.83 | 5.20 |
Full historical valuation and operating metrics for 1987 - 2023 are included in the
US Historical Financials dataset.